Risk factors for ribavirin treatment failure in Asian organ transplant recipients with chronic hepatitis E infection
Risk factors for ribavirin treatment failure in Asian organ transplant recipients with chronic hepatitis E infection作者机构：Department of MedicineNg Teng Fong General HospitalNational University Health SystemSingapore 609606Singapore Centre for Liver Disease Management and Transplant of Medical CityManila 1605Philippines Mount Elizabeth Medical CentreSingapore 228510Singapore Division of Gastroenterology and HepatologyNational University Health SystemSingapore 119228Singapore Department of MedicineNational University of SingaporeSingapore 119077Singapore Centre for Infectious Disease Epidemiology and ResearchNational University of SingaporeSingapore 117549Singapore Department of MedicineYong Loo Lin School of MedicineNational University of SingaporeSingapore 119228Singapore
出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)
年 卷 期：2019年第11卷第6期
页 面：553-561页
主 题：Toxicity Antiviral agents Hepatitis E virus Virus classification Systemic immunity Immune responses Persistent infection
摘 要：BACKGROUND Hepatitis E virus(HEV)infection is a cause of chronic hepatitis in immunosuppressed *** virologic response rates to a 12-wk course of ribavirin therapy were reported to be70%in the *** study describes the outcome of HEV treatment in a transplant center in *** To study the outcome of ribavirin treatment in a series of chronic HEV patients,and the cause of treatment *** We studied all of the transplant recipients who were diagnosed with HEV infection between 2012 to *** outcome of therapy and virologic relapse are monitored for three years after the end of *** Ten transplant recipients(4 liver,5 kidney,and 1 bone marrow transplantation)with positive HEV RNA were *** patients received at least 12 wk of ribavirin therapy,and the remaining patient resolved after reducing immunosuppression *** subjects had prolonged viremia that lasted more than one year,despite continuous ribavirin *** ribavirin-treated patients(44.4%)had HEV RNA relapse after achieving a virologic response by the end of *** overall failure rate is 66.7%.Being a kidney transplant recipient is the strongest risk factor for not achieving an initial sustained virologic response(0/5 treated,Chi-Square test,P0.05).The most common side effect of ribavirin is anemia(100%)(haemoglobin reduction of 3-6.2 g/dL).Seven patients required either a blood transfusion or erythropoietin *** The sustained virologic response rate of 12-wk ribavirin therapy for HEV infection in this Asian series was lower than *** transplant recipients had a higher rate of treatment failure due to higher immunosuppression requirements and adverse effects.
维普期刊数据库